Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Propranolol and thyroid hormone metabolism.

W M Wiersinga1

  • 1Department of Endocrinology, Academisch Medisch Centrum, Amsterdam, The Netherlands.

Thyroid : Official Journal of the American Thyroid Association
|January 1, 1991
PubMed
Summary

Propranolol alters thyroid hormone levels by inhibiting key conversion enzymes, affecting triiodothyronine (T3) and reverse triiodothyronine (rT3) metabolism. These changes, potentially mediated by an unknown metabolite, contribute to the therapeutic effects of beta-blockers in thyrotoxicosis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.

European journal of endocrinology·2021
Same author

Asymmetry indicates more severe and active disease in Graves' orbitopathy: results from a prospective cross-sectional multicentre study.

Journal of endocrinological investigation·2020
Same author

Antithyroid drug treatment for Graves' disease: baseline predictive models of relapse after treatment for a patient-tailored management.

Journal of endocrinological investigation·2018
Same author

Thyroid disease symptoms during early pregnancy do not identify women with thyroid hypofunction that should be treated.

Clinical endocrinology·2017
Same author

Graves' orbitopathy as a rare disease in Europe: a European Group on Graves' Orbitopathy (EUGOGO) position statement.

Orphanet journal of rare diseases·2017
Same author

Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves' orbitopathy?

Journal of endocrinological investigation·2017

Area of Science:

  • Endocrinology
  • Pharmacology
  • Thyroid Hormone Metabolism

Background:

  • Thyroid hormones, primarily thyroxine (T4), are converted to active triiodothyronine (T3) and inactive reverse triiodothyronine (rT3) via deiodination.
  • Beta-blockers, like propranolol, are used to manage hyperthyroid symptoms, but their precise molecular mechanisms are not fully elucidated.
  • The role of propranolol in modulating thyroid hormone levels and deiodination pathways requires further investigation.

Purpose of the Study:

  • To investigate the effects of propranolol on plasma levels of T3 and rT3.
  • To determine the mechanisms by which propranolol influences thyroid hormone metabolism, specifically 5'-deiodination.
  • To explore the potential involvement of propranolol metabolites in these observed effects.

Main Methods:

Related Experiment Videos

  • Dose-dependent analysis of plasma T3 and rT3 levels following propranolol administration.
  • Assessment of the impact of propranolol on the conversion rates of T4 to T3 and rT3 to 3,3'-T2.
  • Evaluation of thyroid hormone transport across the plasma membrane and the direct effects of propranolol and its metabolite 4-hydroxypropranolol.

Main Results:

  • Propranolol demonstrated a dose-dependent decrease in plasma T3 and an increase in plasma rT3.
  • These changes were attributed to the inhibition of 5'-deiodination, affecting T3 production and rT3 clearance.
  • The observed effects were independent of thyroid hormone transport inhibition and not directly caused by propranolol or 4-hydroxypropranolol, suggesting an unidentified metabolite's role.

Conclusions:

  • Propranolol significantly alters thyroid hormone metabolism by inhibiting 5'-deiodination, leading to decreased T3 and increased rT3 levels.
  • Beta-blockers with membrane-stabilizing activity, such as propranolol, ameliorate thyrotoxicosis symptoms, partly through T3 reduction.
  • An unidentified propranolol metabolite may be responsible for the observed inhibition of 5'-deiodination.